Phase II Trial of CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2016
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary) ; Trastuzumab (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 08 Jul 2016 Planned End Date changed from 1 Dec 2015 to 1 Apr 2017.
- 08 Jul 2016 Planned primary completion date changed from 1 Dec 2014 to 1 Nov 2016.